ARS Pharmaceuticals (SPRY) announced the launch of the neffyinSchools program. neffyinSchools provides eligible public and private K-12 schools ...

School administrators and nurses are encouraged to review applicable state laws and regulations to ensure neffy® (epinephrine ...

Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...

The continuance of the Corporation as a British Columbia corporation to be governed by the provisions of the Business ...

Preliminary fourth quarter neffy® net product revenue of approximately $6.5 million Preliminary cash, cash equivalents and ...

ARS Pharmaceuticals has announced the submission of applications seeking the approval of the 2mg epinephrine nasal spray, ...

It was a landmark year for medical advancements in 2024, bringing a wave of innovative treatments that promise to reshape patient care. Among the highlights are groundbreaking drugs such as Tryvio, ...

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions “Building upon ...

ARS Pharmaceuticals, Inc. has announced the filing for approval of neffy® (epinephrine nasal spray) 2 mg in Canada and the United Kingdom, where it will be marketed as EURneffy®. This follows ...

Detailed price information for Ars Pharmaceuticals Inc (SPRY-Q) from The Globe and Mail including charting and trades.

(MENAFN- GlobeNewsWire - Nasdaq) Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in ...

Canada and United Kingdom represent two of the largest markets within the ALK portfolio with plans to expand filings of neffy (epinephrine nasal spray) 2 mg in other key global regions SAN DIEGO ...